COVID-19 Considerations for Basic and Translational Research

 View Only
last person joined: one year ago 

This discussion board is devoted to conversations directly relevant to research. Example topics include:
• Sample/tissue collection
• Model/reagent development
• Highlighting emerging literature
• Data sharing/opportunities for collaboration
• Pre-clinical observations
• Translational insights
• Research hypotheses
  • 1.  COVID-19

    Posted 03-22-2020 14:19
      |   view attached
    I have just been pondering about this (like everyone). I included a couple questions below and a ppt summary I made to generate thought


    Colleen S. Curran, MS, PhD
    NIH Bldg10

    Question 1

    TMPRSS2, epitheliasin is highly expressed in the prostate and driven by androgens.

    PMID: 11322890,  Eur J Biochem. 2001 May;268(9):2687-99.

    TMPRSS2 is involved in COVID-19 membrane fusion

    PMID: 32142651, Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4

    Would prostate cancer patients be more susceptible to COVID-19?

    Is this why there is a higher proportion of men in this study?

    PMID:  32167524, JAMA Intern Med. 2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994.



    Question 2

    COVID-19 utilizes ACE2 to bind to the cell surface

    PMID: 32142651, Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4

    SARS-CoV-induced downregulation of ACE2 promotes lung injury 

    PMID: 16007097 Nat Med. 2005 Aug;11(8):875-9.

    ACE2 cleavage of Angiotensin II generates Angiotensin 1–7 (Ang 1–7; DRVYIHPF),

    PMID: 20599443 Pharmacol Ther. 2010 Oct;128(1):119-28. 

    Angiotensin 1–7 (Ang 1–7; DRVYIHPF) is an implicated cancer therapeutic and immunomodulator

    PMID: 32039680, Curr Drug Targets. 2020 Feb 10.

    PMID: 30420474, Cancer Res. 2019 Feb 15;79(4):706-719.

    Would Angiotensin 1–7 (Ang 1–7; DRVYIHPF) be a therapeutic for COVID-19

    Colleen Curran PhD


    coronavirus-curran-2020-6.pdf   9.74 MB 1 version

  • 2.  RE: COVID-19

    Posted 04-25-2020 19:24
    On your 2nd question what would be therapeutic for COVID 19:

    One possible way to treat COVID 19 could be by blocking amino acids needed to synthesize the virus RNA or its envelop. Such a mechanism already known for herpes simplex viruses (HSV) . This virus duplication is impaired if the cell is not getting amino acid arginine. Amino acid Lysine competes with arginine for absorption and entry into cells. Lysine inhibits HSV growth by knocking out arginine. Now, envelope (E) protein of Covid 19 virus also has arginine and blocking arginine by using LYSINE should be working too and used as COVID 19 treatment.


    Alan Olan